Layout
NOWCOALITION
FOR BIPOLAR DISORDER
NOW Bipolar Pharmacotherapy Safety Concerns and Recommended Monitoring
Common Side Effects
Fine hand tremor, thirst, polyuria, nausea, diarrhea, weight gain
Less Common, Potential y
Nephrotoxicity, teratogenicity, neurotoxicity (serum level related)
Serious Side Effects
Early Signs of Lithium Toxicity
New onset of diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination
Long-term Concerns Require
Decreased thyroid function, nephrotoxicity
Monitoring
Baseline Evaluations
BUN, creatinine; thyroid function; serum pregnancy test or assessment
Monitoring
• 12 hrs post dose serum lithium level for monitoring; 5 to 7 days after initiating treatment
and after each dose change (2 levels to establish therapeutic dose); then every 6 months
• TSH, Ca2+, and weight after 6 months, then annual y
Comments
• Monitoring lithium levels and creatinine every 6 months minimizes the risk associated
• Obtain a lithium level if there is a concern about lithium toxicity, as indicated by new
findings of nausea, diarrhea, or change in tremor in someone previously stable on lithium
• Be alert to signs of possible hypothyroid disorder, as indicated by increased weight, cold
intolerance, or fatigue in someone stabilized on lithium treatment
• Recheck lithium levels if any diuretic medications are started or adjusted
• Long term lithium use may result in hyperparathyroidism and elevated Ca2+ levels; thus
DIVALPROEX/VALPROIC ACID
Common Side Effects
GI symptoms, weight gain, headache, fatigue, dizziness, tremor
Less Common, Potential y
Teratogenicity, pancreatitis, polycystic ovary syndrome (in young women),
Serious Side Effects
Baseline Evaluations
• Initial CBC + platelets, LFTs: be aware of bleeding during first 6 months
Monitoring
• Weigh initial y more often, then every 6 months
Comments
• Reinforce the importance of avoiding pregnancy for female patients
• Many potential y important drug-drug interactions. Tends to increase serum level of other
w w w . N O W B i p o l a r . o r g
NOWCOALITION
FOR BIPOLAR DISORDER
NOW Bipolar Pharmacotherapy Safety Concerns and Recommended Monitoring
CARBAMAZEPINE
Common Side Effects
Dizziness, drowsiness, unsteadiness, nausea, vomiting
Less Common, Potential y
Serious, but very rare dermatological reactions (Stevens-Johnson syndrome, toxic
Serious Side Effects
epidermal necrolysis), teratogenicity, agranulocytosis, neutropenia
Baseline Evaluations
• HLA-B*1502 genotype screening in patients of Asian descent (screen for increased
genetic risk of Stevens-Johnson syndrome)
Monitoring
• Alert to signs of rash early in treatment course
• CBC, platelets, LFTs, serum sodium every 6 months
Comments
• Many important drug-drug interactions. Can significantly decrease serum levels of many
medications, including decreased ef ectiveness of many contraceptives
• Reinforce the importance of contraception for female patients
LAMOTRIGINE
Common Side Effects
General y wel tolerated: initial nausea, dizziness, somnolence, headache sometimes
Less Common, Potential y
• Serious dermatological reactions (Stevens-Johnson syndrome, toxic epidermal
Serious Side Effects
necrolysis) much more frequent if medication is started at ful dose rather than increased
very slowly over time; use standard titration protocol or prepackaged "start-up" packs
Monitoring
• Alert to signs of rash early in treatment: especial y of mucosal membranes, palmar
surfaces, contiguous rash over upper chest and face
Comments
• If medication is discontinued > 3 days, must be restarted with same slow taper as with
w w w . N O W B i p o l a r . o r g
NOWCOALITION
FOR BIPOLAR DISORDER
Adverse Events Associated with Atypical Antipsychotics FDA-Approved for Bipolar Disorder
Olanzapine Risperidone
Quetiapine
Ziprasidone Aripiprazole
Asenapine
Metabolic
Neurologic
Cardiovascular
Hormonal
Adverse Events Associated with Atypical Antipsychotics Used Off-Label for Bipolar Disorder
Clozapine
Iloperidone
Lurasidone
Paliperidone
Metabolic
Neurologic
Cardiovascular
Hormonal
w w w . N O W B i p o l a r . o r g
NOWCOALITION
FOR BIPOLAR DISORDER
Monitoring Protocol for Patients Treated with Atypical Antipsychotics†
Parameter
Baseline
Quarterly
†More frequent assessments may be warranted depending on clinical status
References
1. Correl CU. Individualizing treatment for patients with bipolar disorder: optimizing ef icacy, safety, and tolerability.
Current Psychiatry. 2010;9(11):49-81.
2. McIntyre RS, Konaski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin
3. Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the
safety monitoring of bipolar disorder treatments. Bipolar Disorders. 2009;11:559-565.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists,
North American Association for the Study of Obesity. Diabetes Care. 2004;27:596-601.
w w w . N O W B i p o l a r . o r g
Source: http://www.nowbipolar.net/resources/NOW-safety-tool.pdf
BIJSLUITER: INFORMATIE VOOR DE GEBRUIK(ST)ER Cetirizine diHCl RXT 10 mg, filmomhulde tabletten Cetirizinedihydrochloride Lees de hele bijsluiter zorgvuldig door, want deze bevat belangrijke informatie voor u. • Dit geneesmiddel kan zonder voorschrift verkregen worden. Desondanks moet u Cetirizine diHCl RXT 10 mg, filmomhulde tabletten zorgvuldig gebruiken om een goed resulta
Outdoor Education - Authentic Learning in the Context of Landscape Literary education and sensory experience. Perspective of Where, What, Why, How and When of learning environments. Inter-disciplinary context and the outdoor and Anders Szczepanski, ass visiting prof Outdoor Education, Director The distinctive nature and potential of outdoor education from a teacher perspective